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AIM: Weill 
/Marchesani syndrome (WMS) is a rare
systemic disorder with both autosomal recessive and
dominant inheritances. Accumulation of reactive
oxygen species such as O2
+,H 2O2 and OH
+ causes
lipid peroxidation (LPO), whereas antioxidant en-
zymes (superoxide dismutase (SOD), glutathione
peroxidase (GSHPx)) mediate defence against oxida-
tive stress. Excess tumour necrosis factor (TNF)-a and
NO
+ react with O2
+ and cause further antioxidant
depletion with an increase in mutation frequency by
H2O2. This study investigated the levels of SOD,
GSHPx, catalase (CAT), TNF-a,N O
+ and LPO in
patients with WMS.
Methods: A group of 10 WMS patients (four males, six
females; age, 26.59 /19.0 years) and 10 age-matched
and sex-matched controls (five males, five females;
age, 27.39 /18.2 years) were included. Serum TNF-a
levels were determined by a spectrophotometer
technique using immulite chemiluminescent immu-
nometric assay. Malondialdehyde (MDA) was deter-
mined in plasma; CAT in red blood cells (RBCs), and
SOD and GSHPx in both plasma and RBCs. Total
serum NO
+ levels were evaluated by Griess reaction.
Results: Mean levels of TNF-a (8.39 /0.6 pg/ml) in
WMS patients were significantly (p B /0.001) higher
than controls (4.39 /0.2 pg/ml). Plasma MDA levels in
patients and controls were 5.49 /0.8 and 1.89 /0.6
mmol/l, respectively, and the difference was signifi-
cant (p /0.0002). SOD and GSHPx activities were
significantly lower in both RBCs and plasma of WMS
than in controls (RBC-SOD, 3981.99 /626.6 versus
5261.69 /523.0 U/g haemoglobin (Hb), p /0.0005;
plasma-SOD, 529.49 /49.3 versus 713.49 /55.7 U/g pro-
tein, p /0.0002; RBC-GSHPx, 682.79 /42.0 versus
756.59 /47.6 U/g Hb, p /0.0011; plasma-GSHPx,
107.39 /15.0 versus 131.49 /19.7 U/g protein,






levels were also significantly (p /0.0002) increased
in WMS patients (54.49 /5.7 versus 26.99 /6.7 mmol/l).
RBC-CAT levels were similar between groups (125.69 /
21.3 versus 131.09 /21.5 k/g Hb, p /0.8798).
Conclusions: The elevated LPO, TNF-a and NO
+ with
decreased antioxidant enzyme activities indicated
impaired antioxidative defence mechanisms with an
oxidative injury and cell toxicity in WMS patients.
The use of multiple antioxidants and free radical
scavengers might be helpful in this genetic disorder.
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Introduction
In normal cells, a balance exists between oxidative
damage and antioxidant defence. Although tumour
necrosis factor (TNF)-a and highly potent oxidant
molecules such as superoxide anion (O2
+ ), hydro-
gen peroxide (H2O2) and hydroxyl radical (OH
+) are
produced by the immune system, excessive produc-
tion of oxygen-derived free radical creates a condi-
tion known as oxidative stress, participating in
various diseases and syndromes.
1 7
Antioxidant defences in humans protect directly
and indirectly the host against the damaging influ-
ence of such cytokines and oxidants stated earlier.
1
These enzymes include superoxide dismutase (SOD,
EC1.15.1.1), glutathione peroxidase (GSHPx,
EC1.11.1.9) and catalase (CAT, EC1.11.1.6). First,
SOD catalyses the dismutation of O2
+  to H2O2.
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165GSHPx and CAT then independently convert H2O2 to
H2O.
8 If H2O2 is produced in excess, it reacts with
O2
+  and produces OH
+, which is one of the most
active reactive oxygen species (ROS). The ROS
interacts with nucleic acids, proteins and lipids, thus




+) is one of the most abundant
free radicals in the body.
4,5 Excess NO
+ production
causes respiratory enzyme inhibition of mitochon-
dria, resulting in the cessation of DNA replication.
The rapid reaction of NO
+ with other radicals such as
O2
+  to form the powerful oxidant is the general
mechanism that greatly enhances the toxicity of NO
+.
Although O2
+  is scavenged by SOD, NO
+ is the only
known molecule that can be produced high enough
to out-compete SOD for O2
+ .
9
Weill /Marchesani syndrome (WMS) was first re-
ported by Weill
10 and Marchesani.
11 It is a congenital
connective tissue disease characterised by short
stature, brachydactyly, microspherophakia, glau-
coma, and ectopia lentis. Although we have pre-
viously reported a large family with autosomal
dominant transmission,
12 recessive mode of inheri-
tance has also been described.
13 However, the exact
aetiology of this unique disorder is unknown and the
autosomal dominant form has been linked to muta-
tion within the fibrillin-1 gene on chromosome
15q21.1, whereas autosomal recessive WMS mapped
to chromosome 19p13.3-p13.2.
13,14
In the present study, red blood cell (RBC) activities
of SOD, GSHPx and CAT, and plasma activities of
SOD and GSHPx were measured for the first time in
10 patients with autosomal dominant WMS and
compared with age-matched and sex-matched
healthy controls. Plasma TNF-a, malondialdehyde
(MDA) and NO levels were also investigated.
Patients and methods
Ten patients with WMS (four males, six females) from
two families showing dominant transmission and 10
age-matched and sex-matched healthy control sub-
jects (five males, five females) were included in this
study. Systemic and detailed ocular examinations
were performed in all subjects in both groups. All
patients with WMS had the classical systemic and
ocular findings including brachymorphy (n  /10, all
below or equal to the third percentile), brachydactyly
(n  /10, stubby fingers and/or clumsy feet), spher-
ophakia or microspherophakia (n  /9), high refrac-
tive error (n  /6) and lens subluxation (n  /6) with
iridophacodonesis. Three patients demonstrated bi-
lateral but asymmetric glaucomatous optic nerve
damage with increased intraocular pressure. In addi-
tion, vitreous liquefaction (n  /9), strabismus (n  /2),
microcornea (n  /1), scleral staphyloma (n  /1) and
limited mobility of joints (n  /5) were also present.
All control subjects had normal systemic and ocular
findings.
Blood collection
The laboratory personnel were maintained masked to
the clinical diagnosis and group of the subjects,
matching each blood sample by letter coding, and
so were the clinicians to subsequent levels until the
end of the study. After informed consent was
obtained from all patients and controls, antecubital
whole-blood samples were drawn from a peripheral
vein using a 25-gauge needle, avoiding haemolysis,
into evacuated heparinised plain tubes in the morn-
ing hours (08:30 /10:30) after an overnight fast and 15
min of supine rest. None of the patients and controls
received any topical or systemic medication at least 4
weeks prior to blood collection. The samples were
centrifuged at 3000 g for 10 min at 48C, and the
harvested plasma was collected and kept at  /508C
until the time of analysis.
The erythrocytes were subsequently washed twice
with two volumes of 0.9% sodium chloride solution
to remove the plasma remnants. Following this, the
erythrocytes were haemolysed with two-fold vo-
lumes of ice-cold distilled water. After centrifugation
(5000 g, 10 min, 48C) the supernatant was subdivided
and transferred into polyethylene tubes and frozen at
  /708C to be used in the assay of FRSEs in
erythrocytes (SOD, GSHPx and catalase). The plasma
was used to measure the end product of lipid
peroxidation (LPO) (MDA), TNF-a, total nitrite/ni-
trate levels (NO
 
2   /NO
 
3 ) as an indicator of NO
levels, and antioxidant enzymes (SOD, GSHPx, CAT).
The haemoglobin (Hb) content of whole blood was
also measured, and enzyme activity was determined
per mg Hb.
Cytokine analysis
Cytokine analysis was performed according to the
Immulite† (Diagnostic Products Corporation, Los
Angeles, CA, USA) chemiluminescent enzyme immu-
nometric assay. The technique is based on a solid-
phase (bead) two-site assay. The solid phase, a
polystyrene bead, is coated with a monoclonal
specific antibody. After the incubation for 30 /60
min at 378C, unbound conjugate is then removed by a
centrifugal wash (three times), after which a chemi-
luminescent substrate (a phosphate ester of adaman-
tyl dioxetane) is added, and the test unit is incubated
for a further 10 min. The Immulite† system auto-
matically handles sample and reagent additions, the
incubation and separation step, and measurement of
the photon output via the temperature-controlled
luminometer. It calculates test results for control and
C. Evereklioglu et al.
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stored master curve, and generates a printed report.
15
The values of inter-assay imprecision were similar
to those from the intra-assay study with coefficient of
variation (CV) ranging from 2% to 11.5%. The CV for
the measured cytokine was around 5%. The linearity
is satisfactory, with a regression coefficient higher
than 0.99 (r
2).
There is an excellent practicality of the system and
good stability of the calibration curve (15 days). It is a
good reliable method yielding a good precision along
with a satisfactory detection limit.
16 The antibody
used in the Immulite† for TNF-a is highly specific for
each cytokine and chemokine, with no cross-reactiv-
ity to other cytokines that may be present in the
serum samples.
A master curve is constructed by the manufacturer
using a material calibrated against the National
Institute for Biological Standards and Control. An
adjustment of the calibration slope is made by the
user by measuring two-serum matrix vials (low and
high) designated as ‘adjusters’. It should be men-
tioned that between-run and within-run imprecision




LPO is frequently investigated in biomedical research
and the assays for thiobarbituric acid-reactive sub-
stances (TBARS) are much more widely used than
any other index of LPO in biological samples.
18
Thiobarbituric acid (TBA) reacts with LPO aldehydes,
such as MDA. Therefore, assessment of TBARS is a
useful indice of oxidative deterioration and LPO
determination in body fluids.
Plasma MDA level was measured according to the
method described by Wasowicz et al.
19 The principal
of the method is based on the coupling of TBARS
with TBA. All measurements (standards and samples)
were performed at the upper n-butanol phase of the
reaction mixture. In brief, 50 ml of plasma or an
adequate volume of MDA working standard solution
was introduced into 10 ml glass tubes containing 1 ml
of distilled water. After addition of 1 ml of the
solution containing 29 mmol/l TBARS in acetic acid
and mixing, the samples were placed in a water bath
and heated for 1 h at 95 /1008C. After the samples
were cooled, 25 ml of 5 mol/l HCI was added, and the
reaction mixture was extracted by agitation for 5 min
with 3.5 ml of n-butanol. Butanol phase was
separated by centrifugation at 1500 g for 10 min.
The butanol extract was measured with a spectro-
fluorometer (F-4010 fluorescence spectrophotometer;
Hitachi, Tokyo, Japan) at wavelengths of 525 nm for
excitation. The calibration curve was prepared with
MDA standards of 0 /10 mmol/l. Intra-assay and inter-
assay CVs were 3.5% and 6%, respectively. Results
were expressed as nanomoles per millilitre.
Plasma total nitrite/nitrate (NO
 




Because total nitrite is the stable end product of NO
+
metabolism, NO
+ synthesis was determined as total
nitrite using a spectrophotometric assay based on the
Griess reaction as described previously.
20 24 In short,
samples (250 ml) were incubated at room temperature
with 250 ml of substrate buffer (0.1 mol/l of imidazole,
210 mmol/l of NADPH, 3.8 mmol/l of flavine adenine
dinucleotide; pH 7.6) in the presence of nitrate
reductase (Aspergillus niger; Sigma, St. Louis, MO,
USA) for 45 min to convert nitrate (NO
 
3 ) to nitrite
(NO
 
2 ). Excess reduced NADPH, which interferes
with the chemical detection of nitrite, was oxidised
by continuation of the incubation of 5 mg( 1ml) of
LDH (Sigma), 0.2 mmol/l (120 ml) of pyruvate (Sigma)
and 79 ml of water. Total nitrite was then analysed by
reacting the samples with Griess reagent (1% sulfa-
nilamide, 0.1% naphthalene /ethylene diamine dihy-
drocholoride in 5% H3PO4 spectroquant; Merck,
Darmstadt, Germany). Reacted samples were treated
with 500 ml of trichloroacetic acid (20%), centrifuged
for 15 min at 8000 g and the absorbance at 548 nm
was compared with that of NaNO2 standard (0 /100
mmol/l). Total nitrite/nitrate levels were expressed as
micromoles per litre.
RBCs and plasma-SOD analysis
SOD activity in plasma and supernatant was mea-
sured according to the method of Sun et al.
25 by
determining the inhibition of nitroblue tetrazolium
(NBT) reduction with xanthine /xanthine oxidase
used as an O2
+  generator. Activity was assessed in
the ethanol phase of the lysate after 1.0 ml of ethanol/
chloroform mixture (5/3, v/v) was added to the same
volume of the hemolysate and centrifuged. One unit
of SOD is defined as the amount of protein or Hb that
inhibits the rate of NBT reduction by 50%. Results
were defined as units per gram of protein or
haemoglobin (U/g protein or U/g Hb).
RBCs and plasma GSHPx analysis
GSHPx activity in plasma and supernatant was
measured according to the method of Paglia and
Valentine.
26 Enzyme activity was determined from the
oxidation of reduced NADPH in the presence of
H2O2 used as substrate. The decrease in concentra-
tion of NADPH was monitored and recorded at 340
nm in a mixture containing reducted glutathione and
glutathione reductase (pH 7.8, 258C). Enzyme units
were defined as the number of micromoles of
NADPH oxidised per minute. Results were defined
TNF-a, LPO oxidative stress in Weill /Marchesani syndrome
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g protein or U/g Hb).
RBC-CAT analysis
CAT activity in supernatant was determined accord-
ing to the method of Aebi
27 by monitoring the initial
rate of disappearance of H2O2 (initial concentration,
10 mM) at 240 nm (e  /0.041/mmol  /1/cm) in a
cuvette containing 10.5 mM H2O2 in 1 ml of 50 mM
phosphate buffer (pH 7, 258C), in a spectrophot-
ometer. Results were reported as the constant rate per
second per gram of Hb (K/g Hb). Protein concentra-




The Mann /Whitney U-test was used for the statistics,
and the results expressed as mean9 /standard devia-
tion. The two-tailed statistical significance between
two means was considered pB /0.05. Statistical ana-
lysis was performed with Statistical Package for the
Social Sciences for Windows (release 7.5; SPSS/PC  /
Inc., Chicago, IL, USA).
Results
The mean age between patients (26.59 /19.0 years;
range, 6 /68 years) and controls (27.39 /18.2 years;
range, 8 /65 years) was comparable (p  /0.05). The
mean value of TNF-a (8.39 /0.6 pg/ml) was signifi-
cantly (pB /0.001) higher in WMS than control sub-
jects (4.39 /0.2 pg/ml). RBC activities of SOD
(3981.99 /626.6 U/g Hb) and GSHPx (682.79 /42.0
U/g Hb) were significantly lower in WMS patients
when compared with controls (5261.69 /523.0 U/g
Hb, p  /0.0005 and 756.59 /47.6 U/g Hb, p  /0.0011,
respectively) (Table 1). The RBC-CAT activity of
patients with WMS (125.69 /21.3 k/g Hb) was com-
parable with controls (131.09 /21.5 k/g Hb,
p  /0.8798). The plasma levels of SOD (529.49 /49.3
U/g protein) and GSHPx (107.39 /15.0 U/g protein)
were also significantly lower in WMS patients than
those in controls (713.49 /55.7 U/g protein, p  /0.0002
and 131.49 /19.7 U/g protein, p  /0.0113, respec-
tively). Plasma MDA levels in WMS patients and
controls were 5.49 /0.8 mmol/l and 1.89 /0.6 mmol/l,
respectively, and the difference was significant (p  /
0.0002). Plasma NO concentrations in WMS patients
(54.49 /5.7 mmol/l) were also significantly (p  /
0.0002) higher than in healthy control subjects
(26.99 /6.7 mmol/l).
Discussion
WMS is a very rare systemic connective tissue
disorder with systemic and ocular findings.
12 Brachy-
morphy, brachydactyly and, significantly, myopia
were noted among parents and other relatives,
suggesting that the gene might be dominant with a
severely reduced penetrance or a wide range of
expressivity.
13,29 Alternatively, the syndrome may be
considered incompletely recessive with partial ex-
pression in the heterozygote.
30 Although GEMSS
syndrome (glaucoma /ectopia /microspherophakia /
stiff joints /short stature) has been suggested as an
acceptable name for the autosomal dominant form,
31
the relationship between the dominant and recessive
WMS is not known. Therefore, early differential
diagnosis is mandatory, especially in subtle cases,
for prognostic, therapeutic and genetic reasons
(genetic counselling) in order to make a nosologic
diagnosis and to prevent potentially life-threatening
systemic complications.
Increased oxidative damage with decreased SOD
activity has been suggested in the pathogenesis of
Down syndrome as well as in the ageing process.
32
Electron microscopic study of the microspherophakic
lens obtained from a patient with WMS clearly
demonstrated epithelial cell degeneration, marked
liquefaction and destruction of the subcapsular
cortical fibres.
33 Such degeneration and necrosis of
the cells are caused by various factors including
Table 1. Plasma LPO, NO
+ and antioxidant enzyme activities in plasma and erythrocytes of patients with WMS and controls
Weill /Marchesani syndrome
(n  /10; four male, six female)
Healthy controls
(n  /10; five male, five female)
P*
Age (years) 26.59 /19.0 27.39 /18.2 0.8205
Plasma-MDA (mmol/l) 5.49 /0.8 1.89 /0.6 0.0002
RBCs-SOD (U/g Hb) 3981.99 /626.6 5261.69 /523.0 0.0005
Plasma-SOD (U/g protein) 529.49 /49.3 713.49 /55.7 0.0002
RBC-GSHPx (U/g Hb) 682.79 /42.0 756.59 /47.6 0.0011
Plasma-GSHPx (U/g protein) 107.39 /15.0 131.49 /19.7 0.0113
RBC-CAT (k/g Hb) 125.69 /21.3 131.09 /21.5 0.8798
TNF-a (pg/ml) 8.39 /0.6 4.39 /0.2 B /0.001
Plasma NO (mmol/l) 54.49 /5.7 26.99 /6.7 0.0002
Data presented as mean9 /standard deviation.
* Mann /Whitney U-test.
C. Evereklioglu et al.
168 Mediators of Inflammation Vol 13  2004ageing, inflammation and trauma.
34 Destruction of
the cortical fibres is a common histological change
seen in lenses with senile cortical cataracts.
35 There-
fore, premature ageing process may participate in
WMS.
In the present study, we have studied plasma
LPO and TNF-a levels with the antioxidant system
SOD, CAT and GSHPx in both RBCs and plasma of
patients with WMS. Both plasma and RBCs activities
of SOD and GSHPx were found to be decreased
whereas RBC-CAT activities did not changed.
In addition, plasma MDA, TNF-a and NO
+ levels
were also significantly increased when compared
with controls. Because free radicals play a sign-
ificant role in the multifactorial syndrome, which
constitutes systemic and ocular manifestations,
our results suggest that both RBCs and serum of
WMS patients have an unbalanced antioxidant
system with increased LPO and TNF-a, thus p
articipating in the manifestations of this unique
disease.
Free radicals are mainly derived from a univalent
sequential reduction of molecular oxygen. Mitochon-
dria are the main location of intracellular production,
which may also result from auto-oxidation of small
molecules or function of some enzymes. The free-
radical theory of cell dysfunction is basically found
on three main observations: (1) free radicals are
extremely reactive species; (2) the production of oxy
free radicals, mainly O2
+ , is a constant phenomenon
in the organism with beneficial (defence against
microbial aggression by phagocytes) and damaging
effects at the cellular and molecular levels; and (3)
natural defence or control mechanisms occur by
enzymatic antioxidants. Therefore, an imbalance
between production and control mechanisms is
supposed to result in the continuous or progressive
accumulation of deleterious changes throughout the
cells and tissues, thus generating intense functional
disorder at each level of organisation of ultra
structures, cells and organs.
36
The cell defence system against free-radical-in-
duced toxic LPO (MDA), referred to TBARS, consist
of antioxidative free-radical scavenging molecules
such as SOD, GSHPx and CAT.
37 These enzymes
block the initiation of free-radical chain reactions.
Many syndromes such as Hutchinson /Gilford, Wer-
ner’s and Down’s syndromes are genetically con-
trolled. Because genetic mutations result in
distributed activities of the antioxidative enzymes
such as SOD, GSHPx and CAT, the genomic and free-
radical theories are closely linked as the altered SOD/
(GSHPx plus CAT) ratio may affect gene expression
by altering the binding and/or availability of tran-
scription factors to DNA.
37,38 Indeed, this study
demonstrated that there was a significant increase
in LPO characterised by elevated plasma MDA levels
in patients with WMS when compared with healthy
controls. It is well known that increased production
of free radicals as a result of decreased antioxidant
enzymes SOD and GSHPx can lead to the formation
of LPO.
7 In addition, both erythrocyte and plasma
SOD levels as well as GSHPx activities were sig-
nificantly decreased when compared with controls. If
SOD levels decrease concomitantly with GSHPx,
then the first (O2
+ ) and second step (H2O2) inter-
mediate radicals accumulate. These oxygen free
radicals could undergo the Fenton’s reaction, gen-
erating hydroxyl radicals, which may lead to LPO in
cells. Therefore, the increased plasma LPO levels in
this syndrome may affect the susceptible target
tissues more seriously.
It should be noted that the interaction between
NO
+ and O2
+ , producing a cytotoxic oxidant,
peroxynitrite, has recently received a great deal of
attention.
39 Indeed, decreased SOD and GSHPx
activities paired with increased NO
+ react with
O2
+  and cause further antioxidant depletion and,
therefore, oxidative damage.
There is a debate whether a relation exists between
the activation of the inflammatory mediator cascade
and changes of the organism’s antioxidative system.
Because free radicals are among the key mediators of
a TNF-a-induced killing event, TNF-a-induced apop-
tosis may be mediated by free radicals and LPO in
WMS.
40 In other words, this study suggests that
increased TNF-a may be a key contributor to the
cascade that establishes the tissue injury process of
oxidant-derived cell injury. Thus, immune dysfunc-
tion and increased oxidation and LPO seem to
participate during the course of this disorder.
In conclusion, although much than more is known
about the systemic and ocular manifestations of WMS
with attempts to define still the gene, the exact
aetiology is still unclear and, to our knowledge, there
is no molecular study performed on WMS patients.
Many other biochemical changes within the body,
especially in molecular basis, cannot be ruled out.
Increased LPO and NO
+ levels with decreased
antioxidant enzyme activities found in the present
study may suggest that NO
+,O 2
+  and H2O2 are
generated in excess resulting in oxidative stress in
WMS. These changes may affect cellular macromole-
cules as well as nucleic acids, leading to DNA
mutation and the cessation of DNA replication. Our
results are consistent with the notion that ROS may
contribute to the process of cellular dysfunction in
mammalians. Therefore, further studies in a larger
group of patients are needed in this respect to
confirm this interpretation and hypothesis.
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